Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.

MLA

Keller, Magdalena, et al. “Inhibiting the Glycerophosphodiesterase EDI3 in ER-HER2+ Breast Cancer Cells Resistant to HER2-Targeted Therapy Reduces Viability and Tumour Growth.” Journal of Experimental & Clinical Cancer Research : CR, vol. 42, no. 1, Jan. 2023, p. 25. EBSCOhost, https://doi.org/10.1186/s13046-022-02578-w.

APA

Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., AlWahsh, M., Lambert, J., Lindskog, C., Schmidt, M., Brenner, W., Baumann, M., Zent, E., Zischinsky, M.-L., Hellwig, B., Madjar, K., Rahnenführer, J., … Marchan, R. (2023). Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth. Journal of Experimental & Clinical Cancer Research : CR, 42(1), 25. https://doi.org/10.1186/s13046-022-02578-w

Chicago

Keller, Magdalena, Katharina Rohlf, Annika Glotzbach, Gregor Leonhardt, Simon Lüke, Katharina Derksen, Özlem Demirci, et al. 2023. “Inhibiting the Glycerophosphodiesterase EDI3 in ER-HER2+ Breast Cancer Cells Resistant to HER2-Targeted Therapy Reduces Viability and Tumour Growth.” Journal of Experimental & Clinical Cancer Research : CR 42 (1): 25. doi:10.1186/s13046-022-02578-w.